CD7 and Cowden disease: MSCs are a novel therapeutic approved in the EU, Japan, and Israel for the treatment of CD perianal fistulas and in advanced stage clinical trials for immune-mediated diseases like CD7, however, their mechanism of action in CD is unclear.